Newly Diagnosed Patients:

Zolinza® (vorinostat)

What is Zolinza?

Zolinza (vorinostat) is a histone deacetylase (HDAC) inhibitor being developed by Merck. Some cancer cells display excess HDAC activity, which inhibits the expression of genes that regulate cell growth. In laboratory studies, Zolinza has been shown to inhibit cancer cell growth and to induce cell death.

Other names for Zolinza are SAHA (suberoylanilide hydroxamic acid) and MK0683. Zolinza is given once a day with food.

What do we know about Zolinza’s activity in myeloma?

Laboratory and animal studies show that Zolinza displays additive, and often synergistic, activity when combined with Velcade® (bortezomib), melphalan, or Revlimid® (lenalidomide) and dexamethasone.

Several phase I studies have been conducted with Zolinza in relapsed and/or refractory myeloma. Preliminary data show that:

• The combination of Zolinza and Velcade appears to be active, even in some patients who have previously received Velcade and stopped responding to it.
• The combination of Zolinza, Revlimid, and dexamethasone appears to be an active oral regimen that is well tolerated.

Click here to go to the MMRF Clinical Trial Matching Service.